RxDoctor Payments Data

Raj Vashistha, MD

Interventional Cardiology · Pueblo, CONPI 1033436977

Payments from drug & device makers

$4,462in general payments, 2019–2025

Across 77 payments — averaging $57.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$3K
  • Boston Scientific$464
  • Medtronic$221
  • Shockwave Medical, Inc$186
  • E.r. Squibb & Sons, L.L.C.$171
  • Verge Medical, Inc.$144
  • plus $677 from 15 others

What the payments were for

  • Travel & lodging$2,01645%
  • Food & beverage$2,43455%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,462 in reported general payments places this provider in the 30th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$160,779
Medicare patients
669
Services billed
1,750

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban158$213,881
JardianceEmpagliflozin48$64,975
EntrestoSacubitril/Valsartan24$47,229
Repatha SureclickEvolocumab50$37,039
XareltoRivaroxaban23$21,617
Praluent PenAlirocumab14$20,131
FarxigaDapagliflozin Propanediol15$18,075
BrilintaTicagrelor17$15,123
Metoprolol Succinate449$5,649
Atorvastatin Calcium293$2,882
Ranolazine ErRanolazine21$2,588
Flecainide Acetate32$1,966
Carvedilol166$1,603
Rosuvastatin Calcium124$1,534
Losartan Potassium171$1,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$115$213,881158 claims
Boehringer IngelheimJardiance$32$64,97548 claims
NovartisEntresto$97$47,22924 claims
AstraZenecaFarxiga, Brilinta$14$33,19832 claims
Johnson & JohnsonXarelto$16$21,61723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Pueblo

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →